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Abstract 
Aims: Peroxynitrite - matrix metalloproteinase (MMP) signaling has been shown to 
contribute to myocardial ischemia/reperfusion injury and heart failure and to be 
influenced by hyperlipidemia in preclinical models. Therefore, here we investigated 
the correlation between the markers of peroxynitrite – MMP signaling and 
hyperlipidemia in patients with significant coronary stenosis. Methods: Five minutes 
before percutaneous coronary intervention (PCI), arterial blood samples were 
collected from 36 consecutive coronary artery disease (CAD) patients selected for 
elective PCI. Results: Serum nitrotyrosine positively correlated with MMP-9 activity 
(r=0.54, p=0.01) but not with MMP-2 activity. Nitrotyrosine positively correlated with 
total (r=0.58; p<0.01) and LDL cholesterol (r=0.55; p<0.01), serum triglyceride 
(r=0.47; p<0.05), and creatinine (r=0.42; p<0.05), and negatively correlated with HDL 
cholesterol (r=-0.46; p<0.05) and with left ventricular ejection fraction (LVEF; r=-0.55; 
p<0.05), respectively. MMP-2 activity correlated positively with total (r=0.55; p<0.05) 
and LDL cholesterol (r=0.45; p<0.05). In statin-treated patients, a significantly 
reduced serum nitrotyrosine was found as compared to statin naives, however, MMP 
activities and serum cholesterol levels were not different. MMP-9 activity correlated 
with urea nitrogen (r=0.42; p<0.05) and LVEF (r=-0.73; p<0.01). Serum creatinine 
correlated negatively with LVEF (r=-0.49, p<0.05). Conclusions: This is the first 
demonstration that (i) serum nitrotyrosine correlates with MMP-9 activity, (ii) lipid 
parameters correlate with nitrotyrosine and MMP-2 activity, (iii) myocardial function 
correlates with creatinine, nitrotyrosine, and MMP-9 activity, and (iv) creatinine 
correlates with nitrotyrosine and urea nitrogen with MMP-9 activity in CAD patients. 
Studying the biomarkers of peroxynitrite – MMP pathway in large prospective trials 
may reveal their diagnostic avails. 
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Introduction 
Matrix metalloproteinases (MMPs) are major targets of drug and diagnostic 
development in several pathologies including cardiovascular diseases [1,2]. The 
most abundant MMPs in the human myocardium are MMP-2 and MMP-9, which 
have been shown to play a crucial role in myocardial ischemia/reperfusion injury in 
several animal models [3]. Furthermore, it has been shown that serum MMP-2 
predicts infarct size and ventricular dysfunction in ST-elevation myocardial infarction 
patients [4]. The activation of MMP-2 and MMP-9 may occur not only by proteolysis 
but also due to nitro-oxidative stress via posttranslational modiﬁcation of pro-MMPs 
and the formation of transcriptional complexes [5,6]. 
Nitro-oxidative stress plays a pivotal role in the pathomechanism of several 
cardiovascular diseases including ischemic heart disease [7]. The main effector of 
nitro-oxidative stress is peroxynitrite, which may activate several enzymes including 
MMPs via S-nitrosylation/S-glutathiolation of their tyrosine and/or cystein residues 
[7,8]. Furthermore, peroxynitrite nitrates free tyrosine residues to form nitrotyrosine, 
which is a widely used marker for peroxynitrite generation [9]. 
The contribution of increased nitrotyrosine formation to the development of 
atherosclerosis and thus to coronary artery disease (CAD) has been described in 
patients with hypercholesterolemia-combined CAD [10]. Hyperlipidemia is well-
characterized risk factor for cardiovascular diseases at least in part due to its nitro-
oxidative stress enhancing effect [11,12] and deterioration of cardioprotective 
mechanisms [13,14]. Nevertheless, the correlation between serum nitrotyrosine and 
lipid levels is not consistent in the literature. Moreover, correlations between serum 
nitrotyrosine and MMP-2 and MMP-9 activities are still unknown in CAD patients. 
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Therefore, we have conducted a pilot clinical study to determine the 
correlation between serum nitrotyrosine and MMP-2 and MMP-9 activities in single-
vessel CAD patients subjected to elective percutaneous coronary intervention. 
Furthermore, we have investigated the correlation of serum lipids (total-, LDL-, HDL 
cholesterol; triglyceride) with serum nitrotyrosine as well as with serum MMP-2 and 
MMP-9 activities, respectively. To investigate whether serum nitrotyrosine or MMP-2 
and MMP-9 activities may correlate with cardiac function, we determined left 
ventricular ejection fractions (LVEF). Finally, we have examined if there is a 
difference in serum MMP-2 and MMP-9 activities in statin naive and statin-treated 
CAD patients. 
 
Materials and Methods 
Patients and blood sampling 
 The study was approved by the Ethics Committee of the University of Szeged. 
A written informed consent was obtained from all patients enrolled in the study. The 
investigations were carried out in consecutive patients with single-vessel coronary 
disease elected for percutaneous coronary intervention (PCI). Blood samples were 
collected from patients five minutes before the PCI.  
Inclusion criteria were as follows:  
(1) Class II or III stable angina pectoris by the Canadian Cardiovascular Society 
grading system;  
(2) Single-vessel coronary artery disease defined as ≥70% diameter stenosis by 
visual assessment of the coronary angiogram.  
Exclusion criteria were as follows:  
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(1) angina pectoris or other signs of myocardial ischemia within one week before 
intervention;  
(2) Lown 3–4 ventricular arrhythmia before the intervention;  
(3) severe left ventricular dysfunction (<35% LVEF or New York Heart Association 
functional circulatory stage III-IV);  
(4) treatment with ATP–sensitive potassium channel inhibitors;  
(5) history of myocardial infarction or baseline ST-segment abnormalities;  
(6) serum electrolytes out of the physiologic range;  
(7) serum creatinine level >150 µmol/L;  
(8) hypothyreosis  
(9) angiographically visible collateral vessels interfering with the treated coronary 
artery.  
According to inclusion and exclusion criteria, 36 patients were enrolled into the 
present study. 
 PCI was performed using the standard femoral approach in all patients after 
premedication with 100 mg of aspirin and 75 mg of clopidogrel once a day for two 
days prior to PCI. Serum levels of total-, LDL-, HDL cholesterol, triglyceride, 
creatinine and urea nitrogen were quantitated by enzymatic methods on a Roche 
Hitachi Modular P800 automated analysers (Roche Diagnostics, Indianapolis, IN). 
Additional blood samples were collected from patients 5 minutes before the 
percutaneous coronary intervention from femoral artery. Blood samples were 
centrifuged at 1000g for 15 min, at 4°C then serum samples were collected into 
polypropylene microcentrifuge tubes and stored at -20°C until the performance of 
nitrotyrosine and MMP-2, MMP-9 zymographic measurements.  
Biochemical analyses 
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 To measure circulatory MMP-2 and MMP-9 activities, gelatin zymography was 
performed from serum samples (for a representative zymogram see Fig. 1). 
Gelatinolytic activities of MMPs were examined as previously described [15]. Briefly, 
8% polyacrylamide gels were copolymerized with gelatin (2 mg/ml, type A from 
porcine skin, Sigma-Aldrich), and 40 µg of protein per lane were loaded. An internal 
standard (American Type Culture Collection, Manassas, VA) was loaded into each 
gel to normalize activities between gels. After electrophoresis (150 V, 1.5 h), gels 
were washed with 2.5% Triton X-100 for 3 x 15 min and incubated for 20 h at 37°C in 
incubation buffer (50 mM Tris·HCl, 150 mM NaCl, 5 mM CaCl2, and 0.05% NaN3, 
pH 7.4). Gels were then stained with 0.05% Coomassie brilliant blue (G-250, Sigma-
Aldrich) in a mixture of methanol-acetic acid-water [2.5:1:6.5 (vol/vol)] and destained 
in aqueous 4% methanol-8% acetic acid (vol/vol). For positive controls gelatinase 
zymography standard containing human MMP-2 and -9 (Cat. No.: CC73, Chemicon 
Europe Ltd., Southampton, UK) and MMP-2 standard (Cat. No.: CC071, Chemicon 
Europe Ltd.) were used. For negative control, lanes containing serum samples were 
cut off after renaturation of the gel and were separately incubated for 20 h at 37°C in 
development buffer in the presence of the calcium chelator EGTA (ethylene glycol-
bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid; 10 mM). Gelatinolytic activities 
were detected as transparent bands against the dark-blue background. Band 
intensities were quantified, expressed as the ratio to the internal standard, and 
presented in arbitrary units. 
 To estimate systemic peroxynitrite formation, we have measured free 
nitrotyrosine by ELISA in serum samples as previously described [16,17]. Briefly, 
serum samples were deproteinized by addition of 4 volumes of ice-cold ethanol. 
After centrifugation, supernatants were separated and evaporated under nitrogen 
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flow, then they were dissolved in phosphate buffer. Deproteinised sera were 
incubated overnight with anti-nitrotyrosine rabbit IgG and nitrotyrosine 
acetylcholinesterase tracer in precoated (mouse anti-rabbit IgG) microplates followed 
by development with Ellman’s reagent. Serum nitrotyrosine levels were expressed in 
ng/mL. 
Measurement of cardiac function 
 Echocardiographic examinations were performed prior to PCI on a GE Vivid 3 
(GE Healthcare, Milwaukee, WI) cardiac ultrasound and data was digitally recorded. 
Images were acquired using a 3.5 MHz transducer. Images and cines were obtained 
in standard apical and parasternal two- and four-chamber views. To assess LVEF, 
calculations were performed according to recommendations for chamber 
quantification in consensus. LVEF was calculated using the modified Simpson's 
method. 
Statistical analysis 
 Data are expressed as mean ± S.E.M. Univariate correlations between lipid 
parameters and MMP activities as well as nitrotyrosine were analyzed using the 
Pearson correlation coefficient. Because of the relatively small sample sizes in the 
current pilot study, bootstrapped confidence intervals were calculated, using 1000 
samples with replacement, in order to make robust estimates of the correlation 
coefficients as described elsewhere [18,19]. Linear regression analysis was used to 
estimate the prediction of the selected variables. The effects of statin treatment on 
variables were analyzed by unpaired two-tailed Student’s t-test. 
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Results 
 
Baseline characteristics of the 36 coronary artery disease patients are 
summarized in Table 1. 
 
Correlation between serum nitrotyrosine and MMP-2 or MMP-9 activities 
We have determined whether serum nitrotyrosine correlates with MMP-2 and 
MMP-9 activities in CAD patients. MMP-9 activity correlated positively with 
nitrotyrosine (Fig. 2/A; r=0.535, p=0.010), however, there was no significant 
correlation between serum nitrotyrosine and MMP-2 activity (Fig. 2/B). 
 
Correlation between serum lipids and nitrotyrosine or MMPs activity 
In CAD patients, serum total cholesterol (Fig. 3/A), LDL cholesterol (Fig. 3/B) 
and triglyceride (Fig. 3/C) levels correlated positively (r=0.582, p=0.003; r=0.552, 
p=0.008; r=0.471, p=0.023, respectively), while HDL cholesterol negatively (Fig. 3/D; 
r=-0.455, p=0.033) with serum nitrotyrosine. Serum MMP-2 activity correlated 
positively with serum total cholesterol (Fig. 3/E) and LDL cholesterol (Fig. 3/F) levels 
(r=0.550 p=0.015 and r=0.448, p=0.028, respectively), however, neither serum 
triglyceride (Fig. 3/H) nor HDL cholesterol (Fig. 3/G) showed a significant correlation 
with MMP-2 activity. None of the serum lipid parameters correlated with MMP-9 
activity in CAD patients (Table 2).  
 
Correlation between myocardial function and serum nitrotyrosine or MMPs activity 
Serum nitrotyrosine level (Fig. 4/A) and MMP-9 activity (Fig. 4/C) correlated 
negatively with LVEF (r=-0.548, p=0.010 and r=-0.732, p=0.0002, respectively), 
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however, MMP-2 activity did not correlate with LVEF (Fig. 4/B) in CAD patients. We 
did not find any correlation between serum lipid parameters and LVEF (data not 
shown). 
 
Serum nitrotyrosine or MMPs activity in statin-treated patients 
Fifteen out of the 36 CAD patients involved in the present study were treated 
with different types of statins. In statin-treated patients, a significantly reduced serum 
nitrotyrosine level (Fig. 5/A) was found (from 23.5±4.5 ng/ml to 13.6±5.1 ng/ml; 
p<0.05) as compared to statin naive patients. MMP-2 and MMP-9 activities did not 
show any difference between statin-treated and statin naive patients (Fig. 5/B-C). 
 
Correlation between renal function and serum nitrotyrosine or MMPs activity 
In addition, we tested the correlation of renal function parameters with 
markers of peroxynitrite – MMP pathway and also with LVEF. Serum creatinine 
correlated positively with nitrotyrosine (r=0.422, p=0.036; Fig. 6/A) but not with MMP-
2 and MMP-9 activities (Table 3). Urea nitrogen level correlated positively with MMP-
9 activity (r=0.423, p=0.035; Fig. 6/B) but not with nitrotyrosine or MMP-2 activity 
(Table 3). Serum creatinine correlated negatively with LVEF (r=-0.503, p=0.009; Fig. 
6/C), however, urea nitrogen did not correlate with LVEF (Table 3). 
 
Discussion 
In the present pilot study, we have demonstrated for the first time in the 
literature that (i) serum nitrotyrosine correlates with MMP-9 activity, (ii) serum lipid 
parameters correlate with nitrotyrosine level and MMP-2 activity, (iii) myocardial 
function correlates with nitrotyrosine, MMP-9 activity as well as with creatinine, and 
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(iv) creatinine correlates with nitrotyrosine and urea nitrogen correlates with MMP-9 
activity in CAD patients. 
 
Serum nitrotyrosine correlates with MMP activity 
Here we found a positive correlation of serum nitrotyrosine with MMP-9 
activity but not with MMP-2 activity. This suggests that peroxynitrite activates MMPs 
in humans as well. Previously, a positive correlation between nitrotyrosine content 
and MMP-9 expression was found in instable atherosclerotic plaques derived from 
ischemic heart disease patients, which supports our present results [20]. However, 
the reason why we have not found a significant correlation between peroxynitrite and 
MMP-2 activity is not known. A plausible explanation is that while MMP-9 is an 
abundant enzyme in different cells and tissues including macrophages and 
leukocytes, MMP-2 is an intracellular enzyme mainly in contractile tissues that can 
be activated and released e.g. due to acute myocardial ischemia/reperfusion and 
infarction [8,21-24], however, our CAD patient population did not have severe 
ischemia at the time of tissue sampling, therefore, MMP-2 activation and release can 
be less sensitively detected in the serum. 
 
Serum lipids correlate with nitrotyrosine and MMPs activity 
Hyperlipidemia is a well-characterized risk factor for cardiovascular diseases 
and it has been also demonstrated that it contributes to elevated nitro-oxidative 
stress in humans [10,25]. We have previously shown in rats and in apoB-100 
transgenic mice that hypercholesterolemia increases nitro-oxidative stress, which 
leads to myocardial functional deterioration [26,27]. Here, we have also examined 
the correlation pattern of serum lipids with nitrotyrosine in CAD patients and shown 
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that nitrotyrosine correlated positively with triglyceride, total- and LDL cholesterol 
levels, and negatively with HDL cholesterol. In a previous study [28], an increased 
serum nitrotyrosine level was reported in hypercholesterolemic patients, wherein 
only LDL cholesterol showed significant positive correlation with nitrotyrosine. In 
CAD patients, a minor correlation was found between only serum protein-bound 
nitrotyrosine and triglyceride [10]. A similar correlation was shown by others in 
patients with metabolic syndrome [29]. In our present study, we have measured 
serum free nitrotyrosine, which seems to be a more sensitive marker for systemic 
peroxynitrite generation. 
Here we have found that serum MMP-2 activity correlated positively with total- 
and LDL cholesterol levels. However, neither HDL cholesterol, nor triglyceride levels 
correlated with MMP-2 activity. According to our best knowledge, MMP-2 activity has 
been investigated by only one previous study in CAD patients [30], in which a 
negative correlation between serum MMP-2 activity and HDL cholesterol was found, 
however, other correlations were not assessed. In another study [31], plasma MMP-
2 protein level was shown to correlate negatively with HDL cholesterol in CAD 
patients. Noji et al. [32] measured plasma MMP-2 in CAD patients several days 
before coronary intervention, and interestingly found a positive correlation between 
MMP-2 protein level and HDL cholesterol, however, they did not assess MMP-2 
activity. In our present study, serum MMP-9 activity did not show correlation with any 
of the serum lipids. A similar finding was published previously in 
hypercholesterolemic patients [33]. Two independent studies in patients with CAD 
and acute coronary syndrome showed that MMP-9 protein level positively correlated 
with LDL cholesterol [31,32]. Furthermore, correlation of plasma MMP-9 protein 
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content with triglyceride level has been also shown [31]. However, in these studies, 
the authors did not measure MMP-9 activities, only MMP-9 protein immunoreactivity. 
 
Myocardial function correlates with serum nitrotyrosine and MMPs activity 
Here we have demonstrated first time in the literature in CAD patients that 
cardiac function characterized by LVEF showed a significant negative correlation 
with serum nitrotyrosine. This may suggest that the nitro-oxidative stress is 
detrimental to cardiac function in humans, which is in accordance with preclinical 
studies. Furthermore, we have found here that LVEF correlated negatively with 
MMP-9 activity, however, there was no correlation with MMP-2 activity. This is partly 
in accordance with previous findings that both MMP-2 and MMP-9 protein levels 
correlate with LVEF or left ventricular end-diastolic volume index in cardiac patients 
with acute myocardial infarction or heart failure [34-36]. We have also examined here 
the correlation of serum cholesterol and triglyceride levels with LVEF, however, we 
did not observe any significant correlation among these data. In contrast, Wang et al. 
[37] described a positive correlation of LVEF with serum HDL cholesterol and a 
negative correlation with serum triglyceride in angina patients. 
 
Decreased serum nitrotyrosine in statin-treated patients 
Most CAD patients are treated with various statins. Statins are well-
characterized inhibitors of endogenous cholesterol synthesis and it has been also 
described that they attenuate nitro-oxidative stress [38] as assessed by plasma 
nitrotyrosine level in CAD patients [10]. In accordance, we have found here a 
reduced serum nitrotyrosine level in statin-treated CAD patients compared to statin 
naives. 
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Here we have found that MMP-2 and MMP-9 activities were not significantly 
different in statin-treated CAD patients compared to statin naives, although a 
tendency of decrease was found. In contrast, It has been shown in 48 CAD patients 
undergone coronary artery bypass surgery that protein levels and activities of MMP-
2 and MMP-9 measured both in plasma and in pericardial fluid were reduced after 2-
month pravastatin therapy as compared to untreated patients [39]. Other authors 
have also reported a reduction in plasma MMP-2 and/or MMP-9 protein levels after 
statin treatment of cardiac patients, however, in these studies, only MMP protein 
levels were measured [34-36,40]. 
 
Renal function correlates with serum nitrotyrosine and MMPs activity 
 It has been previously described that renal dysfunction may develop and 
contribute to mortality in patients with myocardial infarction [41]. It is also well known 
that ischemic coronary disease is a leading cause of death in uremic patients [42]. 
Although uremic patients and patients with severe left ventricular dysfunction were 
not enrolled into the present study, we have shown a significant negative correlation 
between serum creatinine level and LVEF for the first time in the literature in CAD 
patients. Moreover, we have found a positive correlation between serum creatinine 
and nitrotyrosine as well as between urea nitrogen and MMP-9 activity in CAD 
patients. These results suggest that both increased nitrotyrosine level and MMP-9 
activity may have diagnostic values for the development of an incipient renal 
dysfunction after myocardial infarction even when the patients have creatinine and/or 
urea nitrogen levels near or within the normal range.  
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Limitations 
The present manuscript provides data from a pilot study, therefore, the number of 
the enrolled patients is relatively low. However, bootstrap analysis of the correlation 
coefficients were preformed, which is a widely accepted statistical method of making 
robust estimates of the coefficients in case of small sample sizes. The correlations 
we found were relatively weak, but statistically significant. This may show that there 
might be several other players in the interactions between the parameters we 
correlated in the present study. Indeed, MMP activity is determined by several 
confounding factors, such as level of the endogenous tissue inhibitors of MMPs 
(TIMPs), Zn2+ availability, phosphorylation status of MMPs, redox state etc. E.g. 
TIMPs may dissociate from MMPs during electrophoresis, therefore, TIMP free or 
TIMP bound MMPs in the serum cannot be assessed by zymography. Nevertheless, 
our results show that serum MMP-2 and -9 activities as measured by zymography 
are valuable diagnostic markers.  
 
Conclusions 
 This is the first demonstration that serum (i) nitrotyrosine correlates with MMP-
9 activity, (ii) lipid parameters correlate with nitrotyrosine level and MMP-2 activity, 
(iii) myocardial function correlates with nitrotyrosine, MMP-9 activity as well as with 
creatinine, and (iv) creatinine correlates with nitrotyrosine and urea nitrogen 
correlates with MMP-9 activity in CAD patients. These findings suggest that 
nitrotyrosine and MMP-2 and MMP-9 activities may be of diagnostic values in 
cardiac and renal function of CAD patients and attenuation of nitro-oxidative stress 
and MMP activities may provide therapeutic benefits in this patient population. Thus, 
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to study markers of peroxynitrite – MMP pathway in large prospective studies may 
reveal their diagnostic avails. 
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Legends 
 
Figure 1 
Representative gelatin zymogram from serum samples of CAD patients. 
Figure 2 
Correlation of serum nitrotyrosine content with MMP-2 and MMP-9 activities. Serum 
MMP-9 activity correlated positively with serum nitrotyrosine (A). Serum MMP-2 
activity (B) did not correlate with serum nitrotyrosine. Continuous line: linear 
regression of data; dotted line: 95% confidence interval. r: Pearson correlation 
coefficient, p: significance, bCI: bootstrapped confidence interval of correlation 
coefficient 
Figure 3 
Correlation of serum nitrotyrosine and MMP-2 activities with serum lipids. Serum 
nitrotyrosine level correlated positively with total- (A) and LDL cholesterol (B) as well 
as with triglyceride (C) and correlated negatively with HDL cholesterol (D). Serum 
MMP-2 activity correlated positively with serum total- (E) and LDL cholesterol levels 
(F). Neither serum triglyceride (G) nor HDL cholesterol (H) showed a significant 
correlation with serum MMP-2 activity. Continuous line: linear regression of data; 
dotted line: 95% confidence interval. r: Pearson correlation coefficient, p: 
significance, bCI: bootstrapped confidence interval of correlation coefficient 
Figure 4 
Correlation of left ventricular ejection fraction (LVEF) with serum nitrotyrosine, and 
serum MMP-2 and MMP-9 activities. Serum nitrotyrosine (A) and MMP-9 (C) activity 
correlated negatively with LVEF. Serum MMP-2 activity did not correlate with LVEF 
26 
(B). Continuous line: linear regression of data; dotted line: 95% confidence interval. r: 
Pearson correlation coefficient, p: significance, bCI: bootstrapped confidence interval 
of correlation coefficient 
Figure 5 
Serum nitrotyrosine levels (A) and serum MMP-2 (B) and MMP-9 (C) activities in 
statin-treated and statin naive CAD patients. Serum nitrotyrosine was significantly 
reduced in statin-treated CAD patients as compared to statin naive patients (*p<0.05, 
data are shown as mean ± S.E.M.). MMP-2 and MMP-9 activities were not changed 
in statin-treated CAD patients as compared to statin naive ones (p=0.409 and 
p=0.564, respectively). 
Figure 6 
Correlation of renal function with serum nitrotyrosine, MMP activities and myocardial 
function. Serum nitrotyrosine correlated positively with serum creatinine (A). Serum 
MMP-9 activity correlated positively with urea nitrogen level (B). Continuous line: 
linear regression of data; dotted line: 95% confidence interval. r: Pearson correlation 
coefficient, p: significance, bCI: bootstrapped confidence interval of correlation 
coefficient 
1 
Table 1 Baseline characteristics of the 36 coronary artery disease patients 
Variables Mean±SD or Occurance (number of individuals) 
Biographic and anamnestic variables  
Age ( years) 67.4 ± 10.5 
Gender, m/f 19/17 
Type 1 diabetes  0/36 
Type 2 diabetes 5/36 
Statin treatment 15/36 
ACE inhibitor treatment 31/36 
ARB treatment 1/36 
Nitrate treatment 18/36 
Hemodynamic variables  
Systolic blood pressure (mmHg) 141.7 ± 11.1 
Diastolic blood pressure (mmHg) 89.8 ± 21.4 
Heart rate (beats/min) 70.4 ± 12.1 
LVEF (%) 56.0 ± 10.5 
Coronary stenosis (%) 63.5 ± 8.0 
Occurrence of hypertension 29/36 
Serum variables  
Total cholesterol (mmol/L) 4.6 ± 0.9 
LDL cholesterol (mmol/L) 2.5 ± 0.8 
HDL cholesterol (mmol/L) 1.3 ± 0.4 
Triglycerides (mmol/L) 1.8 ± 0.8 
3-nitrotyrosine (ng/mL) 17.4 ± 11.3 
Urea nitrogen (mmol/l) 5.9 ± 2.4 
Creatinine (µmol/l) 86.3 ± 27.5 
 
 
  
2 
Table 2 Correlations between serum MMP-9 activity and lipid parameters 
Variables 
Pearson 
correlation 
coefficient 
Bootstrapped 
confidence intervals of 
correlation coefficient 
p 
MMP-9 / total cholesterol 0.171 -0.27-0.49 0.436 
MMP-9 / LDL cholesterol 0.020 -0.38-0.30 0.939 
MMP-9 / HDL cholesterol 0.050 -0.31-0.59 0.840 
MMP-9 / triglyceride 0.024 -0.34-0.40 0.913 
 
Table 3 Correlations between serum nitrotyrosine level, MMPs activities, or LVEF 
and renal function parameters 
Variables 
Pearson 
correlation 
coefficient 
Bootstrapped 
confidence intervals of 
correlation coefficient 
p 
MMP-2 / creatinine 0.125 -0.20-0.45 0.504 
MMP-9 / creatinine 0.118 -0.30-0.48 0.550 
NTyr     / BUN 0.105 -0.22-0.39 0.602 
MMP-2 / BUN 0.071 -0.20-0.42 0.700 
LVEF   / BUN -0.250 -0.57-0.00 0.217 
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